KR101490222B1 - 항균성 퀴놀린 유도체 - Google Patents

항균성 퀴놀린 유도체 Download PDF

Info

Publication number
KR101490222B1
KR101490222B1 KR1020097012967A KR20097012967A KR101490222B1 KR 101490222 B1 KR101490222 B1 KR 101490222B1 KR 1020097012967 A KR1020097012967 A KR 1020097012967A KR 20097012967 A KR20097012967 A KR 20097012967A KR 101490222 B1 KR101490222 B1 KR 101490222B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
formula
amino
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097012967A
Other languages
English (en)
Korean (ko)
Other versions
KR20090086604A (ko
Inventor
제롬 에밀 조르쥬 길레몽
다비드 프란시스 알라인 랑크와즈
이스멧 도랑쥬
코엔라트 요제프 로데윅 마르셀 안드리스
아닐 코울
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38126091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101490222(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20090086604A publication Critical patent/KR20090086604A/ko
Application granted granted Critical
Publication of KR101490222B1 publication Critical patent/KR101490222B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
KR1020097012967A 2006-12-06 2007-12-04 항균성 퀴놀린 유도체 Expired - Fee Related KR101490222B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125499 2006-12-06
EP06125499.1 2006-12-06
PCT/EP2007/063313 WO2008068267A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (2)

Publication Number Publication Date
KR20090086604A KR20090086604A (ko) 2009-08-13
KR101490222B1 true KR101490222B1 (ko) 2015-02-05

Family

ID=38126091

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097012967A Expired - Fee Related KR101490222B1 (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체

Country Status (32)

Country Link
US (1) US8415475B2 (enExample)
EP (1) EP2099758B1 (enExample)
JP (1) JP5466011B2 (enExample)
KR (1) KR101490222B1 (enExample)
CN (2) CN104744361B (enExample)
AP (1) AP2479A (enExample)
AR (1) AR064151A1 (enExample)
AU (1) AU2007328887B2 (enExample)
BR (1) BRPI0720220B8 (enExample)
CA (1) CA2669819C (enExample)
CL (1) CL2007003514A1 (enExample)
CY (1) CY1117766T1 (enExample)
DK (1) DK2099758T3 (enExample)
EA (1) EA016733B1 (enExample)
ES (1) ES2573689T3 (enExample)
HR (1) HRP20160585T1 (enExample)
HU (1) HUE028769T2 (enExample)
IL (1) IL199083A (enExample)
JO (1) JO3271B1 (enExample)
ME (1) ME02498B (enExample)
MX (1) MX2009005978A (enExample)
MY (1) MY181645A (enExample)
NO (1) NO341983B1 (enExample)
NZ (1) NZ576823A (enExample)
PL (1) PL2099758T3 (enExample)
PT (1) PT2099758E (enExample)
RS (1) RS54794B1 (enExample)
SI (1) SI2099758T1 (enExample)
TW (1) TWI406659B (enExample)
UA (1) UA100972C2 (enExample)
WO (1) WO2008068267A1 (enExample)
ZA (1) ZA200903950B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2576491T3 (es) 2012-04-27 2016-07-07 Janssen Pharmaceutica, N.V. Derivados de quinolina antibacterianos
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
JP6362235B2 (ja) * 2014-07-14 2018-07-25 ツーセン ファーマシューティカル カンパニー リミテッド ピリジン誘導体およびその抗マイコバクテリウムにおける使用
KR102631986B1 (ko) * 2015-01-27 2024-01-30 얀센 파마슈티카 엔브이 분산성 조성물
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
EA201891644A1 (ru) * 2016-03-07 2019-04-30 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Антибактериальные соединения и их применение
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
JP2021511364A (ja) * 2018-01-29 2021-05-06 カディラ ヘルスケア リミティド 抗菌剤として有用な複素環式化合物
WO2022084947A1 (en) * 2020-10-22 2022-04-28 Lunella Biotech, Inc. Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US7902225B2 (en) * 2004-01-23 2011-03-08 Janssen Pharmaceutica Nv Mycobacterial inhibitors
BRPI0507076B8 (pt) 2004-01-23 2021-05-25 Janssen Pharmaceutica Nv quinolinas substituídas, seu processo de preparação, composição farmacêutica que as compreende e seu uso como inibidores micobacterianos
UA83875C2 (ru) * 2004-01-29 2008-08-26 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
RS56357B1 (sr) 2004-09-28 2017-12-29 Janssen Pharmaceutica Nv Vezujući domen bakterijske atp sintaze
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Also Published As

Publication number Publication date
CA2669819C (en) 2016-08-30
MY181645A (en) 2020-12-30
TWI406659B (zh) 2013-09-01
BRPI0720220B1 (pt) 2020-06-09
UA100972C2 (ru) 2013-02-25
PL2099758T3 (pl) 2016-08-31
IL199083A (en) 2014-08-31
ME02498B (me) 2017-02-20
CN104744361B (zh) 2021-06-08
AP2009004874A0 (en) 2009-06-30
JO3271B1 (ar) 2018-09-16
MX2009005978A (es) 2009-06-16
US8415475B2 (en) 2013-04-09
RS54794B1 (sr) 2016-10-31
NO20092542L (no) 2009-08-25
US20100048566A1 (en) 2010-02-25
CN104744361A (zh) 2015-07-01
HRP20160585T1 (hr) 2016-06-17
CL2007003514A1 (es) 2008-07-11
HK1208437A1 (en) 2016-03-04
AR064151A1 (es) 2009-03-18
NZ576823A (en) 2012-01-12
CY1117766T1 (el) 2017-05-17
EP2099758B1 (en) 2016-03-09
JP5466011B2 (ja) 2014-04-09
AU2007328887A1 (en) 2008-06-12
KR20090086604A (ko) 2009-08-13
SI2099758T1 (sl) 2016-07-29
WO2008068267A1 (en) 2008-06-12
IL199083A0 (en) 2010-03-28
BRPI0720220B8 (pt) 2021-05-25
ZA200903950B (en) 2010-08-25
ES2573689T3 (es) 2016-06-09
PT2099758E (pt) 2016-06-02
AP2479A (en) 2012-09-27
EA200970535A1 (ru) 2009-10-30
JP2010511668A (ja) 2010-04-15
BRPI0720220A2 (pt) 2013-12-24
NO341983B1 (no) 2018-03-05
AU2007328887B2 (en) 2013-01-17
EA016733B1 (ru) 2012-07-30
DK2099758T3 (en) 2016-06-13
TW200838528A (en) 2008-10-01
CA2669819A1 (en) 2008-06-12
CN101553470A (zh) 2009-10-07
EP2099758A1 (en) 2009-09-16
HUE028769T2 (en) 2017-01-30

Similar Documents

Publication Publication Date Title
JP5466011B2 (ja) 抗菌性キノリン誘導体
KR101514992B1 (ko) 항균성 퀴놀린 유도체
KR102110355B1 (ko) 항균성 퀴놀린 유도체
KR101526175B1 (ko) 항박테리아 퀴놀린 유도체
KR101908350B1 (ko) 항균성 퀴놀린 유도체
KR101490221B1 (ko) 항박테리아 퀴놀린 유도체
KR101553600B1 (ko) 항균성 퀴놀린 유도체
HK1137435A (en) Antibacterial quinoline derivatives
HK1208437B (en) Antibacterial quinoline derivatives
HK1137433B (en) Antibacterial quinoline derivatives
HK1137431B (en) Antibacterial quinoline derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180103

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190103

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20200103

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240131

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240131